|
業務類別
|
Biotechnology |
|
業務概覽
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
| 公司地址
| 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118 |
| 電話號碼
| +1 617 949-2643 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.monterosatx.com |
| 員工數量
| 134 |
| Mr. Matthew Bowen |
Corporate Controller and Principal Accounting Officer |
-- |
10/02/2026 |
| Dr. Markus Warmuth, M.D. |
Director, Chief Executive Officer, Principal Financial Officer and President |
美元 650.00K |
29/04/2026 |
| Dr. Sharon Townson, PhD |
Chief Scientific Officer |
-- |
29/04/2026 |
| Ms. Jennifer Champoux |
Chief Operating Officer |
-- |
29/04/2026 |
| Dr. Philip Nickson, J.D.,PhD |
Chief Business and Legal Officer |
美元 520.00K |
29/04/2026 |
| Dr. Filip Janku, M.D.,PhD |
Chief Medical Officer |
美元 520.00K |
29/04/2026 |
|
|
| Dr. Anthony M. Manning, PhD |
Independent Director |
29/04/2026 |
| Dr. Jan Skvarka, M.B.A.,PhD |
Independent Director |
29/04/2026 |
| Dr. Ali Behbahani, M.B.A.,M.D. |
Independent Director |
29/04/2026 |
| Ms. Christine Siu |
Independent Director |
29/04/2026 |
| Dr. Markus Warmuth, M.D. |
Director, Chief Executive Officer, Principal Financial Officer and President |
29/04/2026 |
| Dr. Kimberly L. Blackwell, M.D. |
Independent Director |
29/04/2026 |
| Dr. Eric A Hughes, M.D.,PhD |
Independent Director |
29/04/2026 |
| Dr. Chandra P. Leo, M.D. |
Independent Director |
29/04/2026 |
| Dr. Andrew N. Schiff, M.D. |
Chairman of the Board |
29/04/2026 |
|
|
|
|
